Cardiac Inflammation, Cardiomyocyte Apoptosis, Left Atrium Dilatation and Hypertrophy, Mitochondrial Dysfunction in the Heart, Mitral Valve Regurgitation
Conditions
Keywords
mitral valve regurgitation, omega 3 fatty acids, fish oil, cardiac, mitochondria, apoptosis, human heart
Brief summary
In the absence of treatment, severe mitral valve regurgitation (MR) results in left atrium (LA) dilatation and hypertrophy, followed ultimately by left ventricular dysfunction and heart failure. One promising intervention for the prevention of the deleterious effects of pressure overload-induced cardiac hypertrophy and heart failure is dietary supplementation with n-3 polyunsaturated fatty acids (PUFAs). However, the molecular targets and mechanisms by which n-3 PUFAs exert their effects are not completely defined. A possible target of n-3 PUFAs is the mitochondrial membrane which has broad implications given that mitochondrial dysfunction and altered metabolism have been associated with cardiac hypertrophy and heart failure. The investigators have recently identified significant mitochondrial dysfunction in the LA of patients with severe MR, as compared to their non-hypertrophied right atrium (RA). However, the investigators have not addressed the possibility that intervention with purified n-3 PUFAs (Lovaza) could improve mitochondrial function. From a mechanistic perspective, the investigators have observed in vitro that n-3 PUFAs accumulate predominately into the mitochondrial membrane of cardiomyocytes where the investigators believe they exert their effects on the biophysical organization of the membrane. Therefore, the CENTRAL HYPOTHESIS is that administering Lovaza to patients with severe MR will reduce apoptosis and improve mitochondrial function in LA (Aim 1). This change in mitochondrial function will be driven by significant biochemical and biophysical remodeling of the mitochondrial membrane (Aim 2).
Interventions
DRUGLovaza group
Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
Sponsors
GlaxoSmithKline
East Carolina University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients age 18+ undergoing minimally invasive mitral valve repair surgery will be enrolled in this study.
Exclusion criteria
* Patients with chronic renal insufficiency * Chronic obstructive pulmonary disease * Previous myocardial infarction * Left ventricular dysfunction (ejection fraction \<40%) * Use of anti-arrhythmic drugs other than beta blockers, and the presence of an implantable defibrillator. * In addition, patients that have a high dietary intake of fish (≥ 2 servings/week) or have been taking n-3 PUFA supplements will be excluded. * Also, patients that are allergic to fish or shellfish, or taking any anticoagulant/antiplatelet medications other than aspirin (e.g. Plavix, Coumadin) will be excluded from this study. * Patients under the age of 18, and women who are pregnant will be excluded from this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Specific Aim 1: To determine if Lovaza treatment reduces markers of inflammation and improves mitochondrial function in atrial myocardium | 15 months |
Secondary
| Measure | Time frame |
|---|---|
| Specific Aim 2: To determine if Lovaza treatment alters the biophysical and biochemical organization of cardiac mitochondrial membranes. The following questions will be addressed using the blood and cardiac tissue samples collected as described above: | 15 months |
Countries
United States
Outcome results
None listed